SAN DIEGO--(BUSINESS WIRE)--Epirium Bio Inc., a clinical-stage biopharmaceutical company focused on mitochondrial biogenesis and complementary therapeutic approaches as a means to addressing neuromuscular diseases and neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its unique, orally available, synthetic flavanol EB 002 ((+)-epicatechin) for the treatment of Duchenne and Becker muscular dystrophy. Orphan-drug designation is granted to support development of medicines for patient populations fewer than 200,000 people in the U.S. The company will initially focus on advancing its treatment in Becker muscular dystrophy.